Vision Sciences (CGNT) Earning Positive News Coverage, Study Finds

Media headlines about Vision Sciences (NASDAQ:CGNT) have been trending positive on Thursday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vision Sciences earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 44.7057331506653 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Several equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Vision Sciences from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Monday. Roth Capital cut shares of Vision Sciences from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research report on Friday, March 23rd. Finally, Aegis cut shares of Vision Sciences from a “buy” rating to a “hold” rating and set a $4.75 price target on the stock. in a research report on Tuesday, March 13th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.50.

Shares of CGNT stock remained flat at $$3.90 during trading hours on Thursday. 120,337 shares of the stock traded hands, compared to its average volume of 199,174. Vision Sciences has a twelve month low of $1.55 and a twelve month high of $3.92. The company has a market capitalization of $234.49, a PE ratio of -390.00 and a beta of 0.58.

TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is owned by of BBNS. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://baseballnewssource.com/2018/04/06/cogentix-medical-cgnt-getting-favorable-media-coverage-study-finds/2029139.html.

Vision Sciences Company Profile

Cogentix Medical, Inc, a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use.

Insider Buying and Selling by Quarter for Vision Sciences (NASDAQ:CGNT)

Receive News & Ratings for Vision Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.